Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 1143-1149

  Cowie, F J ^b   Pritchard Jones, K ^a   Renshaw, J ^a   Pinkerton, C R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemosensitisation; Multidrug resistance; Neuroblastoma; Rhabdomyosarcoma

Indexed keywords

CYCLOSPORIN; DOXORUBICIN; VERAPAMIL; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; NEUROBLASTOMA; NORTHERN BLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA;

EID: 0031966635     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.5.1143     Document Type: Article

References (41)

1. Chan HS, Thorner PS, Haddad G and Ling V: Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689-704, 1990.
2. Stein U, Shoemaker RH and Schlag PM: MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas. Eur J Cancer 32: 86-92, 1996.
3. Bourhis J, Benard J, Hartmann O, Boccon-Gibod L, Lemerle J and Riou G: Correlation of MDR 1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 81: 1410-1405, 1989.
4. Chan HS, Haddad G, Thomer PS, deBoer G, Lin YP, Ondrusek N, Yeger H and Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614, 1991.
5. Roessner A, Ueda K, Bockhorn-Dworniczak B, Blasius S, Peters A, Wuisman P, Ritter J, Paulussen M, Jurgens H and Bocker W: Prognostic implication of immunodetection of P-glycoprotein in Ewing's sarcoma. J Cancer Res Clin Oncol 119: 185-189, 1993.
6. Serra M, Scotlandi K, Manara MC, Maurici D, Benini S, Sarti M, Campanacci M and Baldini N: Analysis of P-glycoprotein expression in osteosarcoma. Eur J Cancer 31: 1998-2002, 1995.
7. Kuttesch JFJ, Parham DM, Xiaolong L, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT and Houghton PJ: P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 14: 886-900, 1996.
8. Loe DW, Deeley RG and Cole SPC: Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32: 945-957, 1996.
9. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, van der Valk P and Scheper RJ: Major vault protein LRP-related multidrug resistance. Eur J Cancer 32: 979-984, 1996.
10. Matthay KK, O'Leary MC and Ramsay NK: Role of myeloablative therapy in improved outcome for high risk neuroblastoma: reviews of recent Children's Cancer Group results. Eur J Cancer 31: 572-575, 1995.
11. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R, Morris Jones P, Lawrence W, Newton W, Ortega J, Raney RB, Ruymann FB, Tefft M, Webber B, Wiener E, Wharam M, Vietti TJ and Maurer HM: The third intergroup rhabdomyosarcoma study. J Clin Oncol 13: 610-630, 1995.
12. Twentyman PR, Fox NE and Bleehen NM: Drug resistance in human lung cancer cell lines: cross resistance studies and effects of the calcium transport blocker, verapamil. Int J Rad Oncol Biol Phys 12: 1355-1358, 1986.
13. Twentyman PR, Fox NE, Wright KA and Bleehen NM: Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer 53: 529-537, 1986.
14. Reeve JG, Rabbitts PH and Twentyman PR: Amplification and expression of mdrl gene in a multidrug resistant variant of small cell lung cancer cell line NC1-H69. Br J Cancer 60: 339-342, 1989.
15. Garvin AJ, Stanley WS, Bennett DD, Sullivan JL and Sens DA: The in vitro growth, heterotransplantation and differentiation of a human rhabdomyosarcoma cell line. Am J Pathol 125: 208-217, 1986.
16. Kelland LR, Bingle L, Edwards S and Steel GG: High intrinsic radiosensitivity of a newly established and characterised human embryonal rhabdomyosarcoma cell line. Br J Cancer 59: 160-164, 1989.
17. Biedler JL, Helson L and Spengler BA: Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33: 2643-2652, 1973.
18. Biedler JL, Roffler-Tarlov S, Schachner M and Freedman LS: Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38: 3751-3757, 1978.
19. Deacon JM, Wilson PA and Peckham MJ: The radiobiology of human neuroblastoma. Radiother Oncol 3: 209-210, 1985.
20. Chan HSL, Bradley G, Thorner P, Haddad G, Gallie BL and Ling V: A sensitive method for immunohistochemical detection of P-glycoprotein in multidrug resistant human ovarian carcinoma cell lines. Lab Investigation 59: 870-875, 1988.
21. Kartner N, Everden-Porelle D, Bradley G and Ling V: Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature 316: 820-823, 1985.
22. Van der Valk MA, van Kalken CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJLM, Pindeo HM and Scheper RJ: Distribution of multidrug resistance associated P glycoprotein in normal and neoplastic human tissues. Ann Oncol 1: 56-64, 1990.
23. Hamada H and Tsuruo T: Functional role for the 170-180 kDa glycoprotein specific to drug resistant tumour cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785-7789, 1986.
24. Wilkinson M: RNA isolation: a mini-prep method. Nucleic Acids Res 16: 10933, 1988.
25. Van der Bliek, AM, van der Velde-Koerts T, Ling V and Borst P: Overexpression and amplification of five genes in a multidrug resistant Chinese hamster ovary cell line. Mol Cell Biol 6: 1671-1678, 1986.
26. Chen C, Chin J, Ueda K, Clark DP, Pastan I, Gottesman MM and Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdrl (P-glycoprotein) gene from multidrug resistant human cells. Cell 47: 381-389, 1986.
27. Roninson IR, Chin JE, Choi K, Gros P, Housman DE, Fojo A, Shen D, Gottesman MM and Pastan IH: Isolation of human mdr DNA sequences amplified in multidrug resistant KB carcinoma cells. Proc Natl Acad Sci USA 83: 4538-4524, 1986.
28. Pieters R, Huismans DR, Leyva A and Veerman AJP: Comparison of the rapid automated MTT assay with a dye exclusion assay for chemosensitivity testing in childhood leukaemia. Br J Cancer 59: 217-220, 1989.
29. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R and Weinstein R: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumours: consensus recommendations. Cancer Res 56: 3010-3020, 1996.
30. Toth K, Vaughan MM, Slocum HK, Fredericks WJ, Chen Y, Arredondo MA, Harstrick A, Karakousis C, Baker RM and Rustum YM: Comparison of an immunoperoxidase sandwich staining method and Western blot detection of P glycoprotein in human cell lines and sarcomas. Am J Pathol 140: 1009-1016, 1992.
31. Brophy NA, Marie JP, Rojas RA, Warnke RA, McFall PJ, Smith SD and Sikic BI: Mdrl gene expression in childhood acute lymphoblastic leukemias and lymphoma: a critical evaluation by four techniques. Leukemia 8: 327-335, 1994.
32. Vergier B, Cany L, Bonnet F, Robert J, de Mascarel A and Coindre JM: Expression of MDR1/P glycoprotein in human sarcomas. Br J Cancer 68: 1221-1226, 1993.
33. Cowie FJ, Pinkerton CR, Phillips M, Dick G, Judson I, McCarthy PT and Flanagan RJ: Continuous infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 71: 877-881, 1995.
34. Cowie F and Pinkerton CR: Enhanced toxicity of dactinomycin and vincristine by cyclosporin given to reverse multidrug resistance. J Clin Oncol 12: 1998-1999, 1994.
35. Cairo MS, Siegel S, Anas N and Sender L: Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 49: 1063-1066, 1989.
36. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ and Salmon SE: P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24, 1991.
37. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J and Sikic BI: Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12: 835-842, 1994.
38. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J and Sikic BI: Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. J Clin Oncol 72: 3502-3514, 1993.
39. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, deAngelis C and Bunting P: Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53: 4837-4842, 1993.
40. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth, JF, Brampton MH and Bleehen NM: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610-618, 1996.
41. Theis JG, Liau Chu M, Chan HS, Doyle J, Greenberg ML and Koren G: Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J Clin Oncol 13: 2508-2516, 1995.